Home | Drug Resource
Find:  
Anthrax > Diagnosis Author: Sandro Cinti, MD; Barbara Robinson-Dunn, PhD; Niklas Mackler, MD
Module updated - 2009-11-19
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Rationale:

  • Anthrax is commonly found in Africa, Asia, South America, and the Middle East where it exists in the soil.
  • Textile workers, woolsorters, and agricultural workers are at risk of exposure to anthrax with exposure to animal hides.
  • A powdered form of anthrax has been produced as a biological weapon.
  • During the U.S. anthrax outbreak of 2001, certain groups were at a higher risk for cutaneous and inhalational anthrax.

Evidence:

  • A review detailing the epidemiology, pathogenesis, and clinical characteristics of anthrax identifies the Middle East, Africa, South America, and Asia as regions where anthrax is endemic (21).
  • A historical editorial emphasizes that textile workers are at an increased risk of anthrax (22).
  • At least 66 people died in Sverdlovsk, Russia, of inhalational anthrax as a result of an accidental release from a facility producing anthrax as a biological weapon. Although this outbreak was initially reported as a naturally occurring outbreak of GI anthrax, a subsequent epidemiologic investigation suggested that aerosolized anthrax had been accidentally released from a Russian bioweapons plant (18).
  • During the U.S. anthrax outbreak of 2001, postal workers and media employees were at an increased risk of exposure to powdered anthrax. An epidemiologic investigation showed that postal workers in Washington, DC, were at risk of coming into contact with anthrax spores from contaminated envelopes. Environmental sampling showed contamination of several facilities in Washington, DC. (23).

Comments:

  • None.

FAQs
Barbara Robinson-Dunn, PhD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Nicholas John Vietri, MD, MS, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Niklas Mackler, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Sandro Cinti, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Deborah Korenstein, MD, FACP, Co-Editor, PIER, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Richard B. Lynn, MD, FACP, Co-Editor, PIER, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted © 2012 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.